Immune tolerance induction for patients with severe hemophilia A: A critical literature review

Journal of Thrombosis and Thrombolysis

Volumn 32, Issue 4, 2011, Pages 439-447

  Franchini, Massimo ^b   Lippi, Giuseppe ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b NONE

Author keywords

Eradication; FVIII; Hemophilia A; Immune tolerance induction; Inhibitor; ITI; Therapy

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; RECOMBINANT BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR;

CONTINUOUS INFUSION; DISEASE REGISTRY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; HEMOPHILIA A; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; PRIORITY JOURNAL; PROTEIN FUNCTION; RACE DIFFERENCE; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; TREATMENT OUTCOME;

EID: 82955162691     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-011-0624-3     Document Type: Review

References (75)

1. Coppola A, Di Minno MND, Santagostino E (2010) Optimizingmanagement of immune tolerance induction in patients withsevere hemophilia A and inhibitors: towards evidence-basedapproaches. Br J Haematol 150:515-528
2. Tagliaferri A, Rivolta GF, Iorio A, Italian Association ofHemophilia Centers et al (2010) Mortality and causes of death inItalian persons with haemophilia, 1990-2007. Haemophilia16:437-446
3. Franchini M, Lippi G (2009) Recent improvement in the clinicaltreatment of coagulation factor inhibitors. Semin Thromb Hemost35:806-813
4. Franchini M, Mannucci PM (2010) Inhibitors of propagation ofcoagulation (factors VIII, IX and XI): a review of current therapeuticpractice. Br J Clin Pharmacol (Epub ahead of print)
5. Lusher JM (2000) Inhibitor antibodies to factor VIII and factorIX: management. Semin Thromb Hemost 26:179-188 (Pubitemid 30439356)
6. Salomon O, Zivelin A, Livnat T et al (2003) Prevalence, causes, and characterization of factor XI inhibitors in patients withinherited factor XI deficiency. Blood 101:4783-4788 (Pubitemid 36857735)
7. Wight J, Paisley S (2003) The epidemiology of inhibitors inhaemophilia A: a systematic review. Haemophilia 9:418-435 (Pubitemid 36874391)
8. Key NS (2004) Inhibitors in congenital coagulation disorders. BrJ Haematol 127:379-391 (Pubitemid 39539246)
9. Coppola A, Santoro C, Tagliaferri A, Franchini M, Di Minno G(2010) Understanding inhibitor development in haemophilia A:towards clinical prediction and prevention strategies. Haemophilia16(Suppl 1):13-19
10. Kempton CL, White CG (2009) How we treat a hemophilia Apatient with a factor VIII inhibitor. Blood 113:11-17
11. Kruse-Jarres R, Barnett B, Leissinger C (2008) Immune toleranceinduction for the eradication of inhibitors in patients withhemophilia A. Expert Opin Biol Ther 8:1885-1896
12. Haya S, Moret A, Cid AR et al (2007) Inhibitors in haemophiliaA: current management and open issues. Haemophilia 13(Suppl. 5):52-60 (Pubitemid 350253405)
13. Mariani G, Siragusa S, Kroner BL (2003) Immune toleranceinduction in hemophilia A: a review. Semin Thromb Hemost29:69-76
14. DiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E(2007) International workshop on immune tolerance induction:consensus recommendations. Haemophilia 13(Suppl 1):1-22 (Pubitemid 47009242)
15. Di Paola J, Aledort L, Britton H et al (2006) Application ofcurrent knowledge to the management of bleeding events duringimmune tolerance induction. Haemophilia 12:591-597 (Pubitemid 44697529)
16. Brackmann HH, Oldenburg J, Schwaab R (1996) Immune tolerancefor the treatment of factor VIII inhibitors-twenty years''Bonn protocol'. Vox Sang 70(Suppl 1):30-35 (Pubitemid 26055992)
17. Nilsson IM, Berntorp E, Zettervall O (1988) Induction of immunetolerance in patients with hemophilia and antibodies to factorVIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. N Engl J Med 318:947-950 (Pubitemid 18094988)
18. Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, van den Berg HM (1995) Low-dose immune toleranceinduction in hemophilia A patients with inhibitors. Blood 86:983-988
19. Ewing NP, Sanders NL, Dietrich SL, Kasper CK (1988) Inductionof immune tolerance to factor VIII in hemophiliacs withinhibitors. JAMA 259:65-68
20. Unuvar A, Warrier I, Lusher JM (2000) Immune toleranceinduction in the treatment of paediatric haemophilia A patientswith factor VIII inhibitors. Haemophilia 6:150-157 (Pubitemid 30312467)
21. Rocino A, Papa ML, Salerno E, Capasso F, Miraglia E, De BiasiR (2001) Immune tolerance induction in haemophilia A patientswith high-responding inhibitors to factor VIII: experience at asingle institution. Haemophilia 7:33-38 (Pubitemid 32162195)
22. Batlle J, Lopez MF, Brackmann HH et al (1999) Induction ofimmune tolerance with recombinant factor VIII in haemophilia Apatients with inhibitors. Haemophilia 5:431-435 (Pubitemid 30003772)
23. Astermark J, Morado M, Rocino A, on behalf the EHSTB et al(2006) Current European practice in immune tolerance inductiontherapy in patients with hemophilia and inhibitors. Haemophilia12:363-371
24. Mariani G, Ghirardini A, Bellocco R (1994) Immune tolerance inhemophilia-principal results from the international registry. Thromb Haemost 72:155-158
25. Mariani G, Kroner B (1999) International immune toleranceregistry, 1997 update. Vox Sang 77(Suppl 1):25-27 (Pubitemid 29469251)
26. Mariani G, Kroner B (2001) Immune tolerance in hemophiliawith factor VIII inhibitors: predictors of success. Haematologica86:1186-1193 (Pubitemid 33063865)
27. DiMichele DM, Kroner B, North American Immune ToleranceStudy Group (2002) The North American immune toleranceregistry: practices, outcomes, outcome predictors. Thromb Haemost87:52-57 (Pubitemid 34092575)
28. DiMichele D (2009) The North American Immune ToleranceRegistry: contributions to the thirty-year experience with immunetolerance therapy. Haemophilia 15:320-328
29. Lenk H, ITT Study Group (2000) The German registry ofimmune tolerance treatment in hemophilia-1999 update. Haematologica85(Suppl 10):45-47
30. Haya S, Lopez MG, Aznar JA, Battle J (2001) Immune tolerancetreatment in haemophilia patients with inhibitors: the Spanishregistry. Haemophilia 7:154-159 (Pubitemid 32243797)
31. Coppola A, Margaglione M, Santagostino E, AICE PROFITStudy Group et al (2009) Factor VIII gene (F8) mutations aspredictors of outcome in immune tolerance induction of hemophiliaA patients with high-responding inhibitors. J Thromb Haemost 7:1809-1815
32. DiMichele DM, Hay CR (2006) The international immune tolerancestudy: a multicenter prospective randomized trial in progress. J Thromb Haemost 4:2271-2273 (Pubitemid 44400309)
33. DiMichele DM, Goldberg I, Foulkes M, Hay CRM, on behalf ofthe International Immune Tolerance Study Group (2010) Internationalprospective randomized immune tolerance (ITI) study:preliminary results of therapeutic efficacy and safety. Haemophilia16(Suppl. 4):29 (abstract 07S03)
34. Gringeri A (2007) VWF/FVIII concentrates in high-risk immunotolerance:the RESIST study. Haemophilia 13(Suppl. 5):73-77 (Pubitemid 350253409)
35. Kroner BL (1999) Comparison of the international immune toleranceregistry and the North American immune tolerance registry. Vox Sang 77(Suppl 1):33-37 (Pubitemid 29469254)
36. Kreuz W, Ehrenforth S, Funk M et al (1995) Immune tolerancetherapy in paediatric haemophiliacs with factor VIII inhibitors:14 years follow-up. Haemophilia 1:24-32
37. Callaghan MU, Rajpurkar M, Chitlur M, Warrier I, Lusher J(2011) Immune tolerance induction in 31 children with haemophiliaA: is ITI less successful in African Americans? Haemophilia17:483-489
38. DiMichele DM (2006) Immune tolerance: critical issues of factordose, purity and treatment complications. Haemophilia 12(Suppl6):81-85
39. Berntorp E (2001) Immune tolerance induction: recombinant vs. human-derived product. Haemophilia 7:109-113 (Pubitemid 32162207)
40. Barnes C, Rivard GE, Poon MC et al (2006) Canadian multiinstitutionalsurvey of immune tolerance therapy (ITT)-experiencewith the use of recombinant factor VIII for ITT. Haemophilia12:1-6
41. Kreuz W, Ettingshausen CE, Auerswald G et al (2003) Epidemiologyof inhibitors and current treatment strategies. Haematologica88:EREP04
42. Auerswald G, Spranger T, Brackmann HH (2003) The role ofplasma-derived factor VIII/von Willebrand factor concentrates inthe treatment of hemophilia A patients. Haematologica88:EREP05
43. Berntorp E, Nilsson IM (1996) Immune tolerance and theimmune modulation protocol. Vox Sang 70(Suppl 1):36-41 (Pubitemid 26055993)
44. Orsini F, Rotschild C, Beurrier P, Faradji A, Goudemand J, Polack B (2005) Immune tolerance induction with highly purifiedplasma-derived factor VIII containing von Willebrand factor inhemophilia A patients with high-responding inhibitors. Haematologica90:1288-1290 (Pubitemid 41375296)
45. Greninger DA, Saint-Remy JM, Jacquemin M, Benhida A, DiMichele DM (2008) The use of factor VIII/von Willebrandfactor concentrate for immune tolerance induction in haemophiliaA patients with high-titre inhibitors: association of clinical outcomewith inhibitor epitope profile. Haemophilia 14:295-302 (Pubitemid 351338690)
46. Kurth MA, Dimichele D, Sexauer C et al (2008) Immune tolerancetherapy utilizing factor VIII/von Willebrand factor concentratein haemophilia A patients with high titre factor VIIIinhibitors. Haemophilia 14:50-55
47. Gringeri A, Musso R, Mazzucconi MG et al (2007) Immunetolerance induction with a high purity von Willebrand factor/VIIIcomplex concentrate in haemophilia A patients with inhibitors athigh risk of a poor response. Haemophilia 13:373-379 (Pubitemid 47040164)
48. Oldenburg J, Schwaab R, Brackmann HH (1999) Induction ofimmune tolerance in haemophilia A inhibitor patients by the'Bonn Protocol': predictive parameter for therapy duration andoutcome. Vox Sang 77(Suppl 1):49-54 (Pubitemid 29469258)
49. Rocino A, Santagostino E, Mancuso ME, Mannucci PM (2006)Immune tolerance induction with recombinant factor VIII inhemophilia A patients with high responding inhibitors. Haematologica91:558-561
50. Valentino LA, Recht M, Dipaola J et al (2009) Experience with athird generation recombinant factor VIII concentrate (Advate) forimmune tolerance induction in patients with haemophilia A. Haemophilia 15:718-726
51. Smith MP, Spence KJ, Waters EL et al (1999) Immune tolerancetherapy for hemophilia A patients with acquired factor VIII alloantibodies:comprehensive analysis of experience at a singleinstitution. Thromb Haemost 8:35-38 (Pubitemid 29041646)
52. Platokouki H, Pergantou H, Xafaki P, Komitopoulou A, Aronis S(2009) Immune tolerance inductionwith high vonWillebrand factor/factor VIII content ratio concentrate in children with haemophilia Aand high-responding inhibitor. Haemophilia 15:617-619
53. Rothschild C, Laurian Y, Satre EP et al (1998) French previouslyuntreated patients with severe hemophilia A after exposure torecombinant factor VIII: incidence of inhibitor and evaluation ofimmune tolerance. Thromb Haemost 80:779-783 (Pubitemid 28521722)
54. Courter SG, Bedrosian CL (2001) Clinical evaluation ofB-domain deleted recombinant factor VIII in previously untreatedpatients. Semin Hematol 38(Suppl 4):52-59 (Pubitemid 32618681)
55. Borel-Derlon A, Lambert T, Rocino A et al (2004) Retrospectiveassessment of immune tolerance induction with recombinantrAHF, a highly purified, full-length recombinant FVIII, inhemophilia A patients with inhibitors. Haemophilia 10(Suppl3):53-66
56. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS, the KogenatePreviously Untreated Patient Study Group (1993) Recombinantfactor VIII for the treatment of previously untreated patients withhemophilia A. Safety, efficacy, and development of inhibitors. N Engl J Med 328:453-459 (Pubitemid 23056434)
57. Ter Avest PC, Fischer K, Gouw SC, Van Dijk K, Mauser-Bunschoten EP (2010) Successful low dose immune toleranceinduction in severe haemophilia A with inhibitors below 40Bethesda Units. Haemophilia 16:71-79
58. Unuvar A, Kavakli K, Baytan B et al (2008) Low-dose immunetolerance induction for paediatric haemophilia patients with factorVIII inhibitors. Haemophilia 14:315-322 (Pubitemid 351338692)
59. DiMichele D (2007) Immune tolerance therapy for factor VIIIinhibitors: moving from empiricism to an evidence-basedapproach. J Thromb Haemost 5(Suppl 1):143-150 (Pubitemid 46958827)
60. Franchini M, Lippi G (2010) Von Willebrand factor-containingfactor VIII concentrates and inhibitors in haemophilia A. Acritical literature review. Thromb Haemost 104:931-940
61. Lin Y, Yang X, Chevrier MC et al (2004) Relationships betweenfactor VIII:Ag and factor VIII in recombinant and plasma-derivedfactor VIII concentrates. Haemophilia 10:459-469 (Pubitemid 39317754)
62. Astermark J, Voorberg J, Lenk H et al (2003) Impact of inhibitorepitope profile on the neutralizing effect against plasma-derivedand recombinant factor VIII concentrates in vitro. Haemophilia9:567-572 (Pubitemid 37236091)
63. Gensana M, Altisent C, Aznar JA et al (2001) Influence of vonWillebrand factor on the reactivity of human factor VIII inhibitorswith factor VIII. Haemophilia 7:369-374 (Pubitemid 32677655)
64. Kallas A, Talpsep T (2001) von Willebrand factor in factor VIIIconcentrates protects against neutralization by factor VIII antibodiesof haemophilia A patients. Haemophilia 7:375-380 (Pubitemid 32677656)
65. Berntorp E (1997) Second generation, B-domain deleted recombinantfactor VIII. Thromb Haemost 78:256-260 (Pubitemid 27289250)
66. Suzuki T, Arai M, Amano K, Kagawa K, Fukutake K (1996)Factor VIII inhibitor antibodies with C2 domain specificity areless inhibitory to factor VIII complexed with von Willebrandfactor. Thromb Haemost 76:749-754 (Pubitemid 26388181)
67. Reding MT (2006) Immunological aspects of inhibitor development. Haemophilia 12(Suppl 6):30-36 (Pubitemid 44741500)
68. Ghio M, Contini P, Ottonello L et al (2003) Effect of clottingfactor concentrates on lymphocyte and neutrophil function invitro. Thromb Haemost 89:365-373
69. Thorpe R, Dilger P, Dawson NJ, Barrowcliffe TW (1989) Inhibitionof interleukin-2 secretion by factor VIII concentrates: apossible cause of immunosuppression in haemophiliacs. Br JHaematol 71:387-391 (Pubitemid 19086652)
70. Dasgupta S, Repesse Y, Bayry J et al (2007) VWF protects FVIIIfrom endocytosis by dendritic cells and subsequent presentationto immune effectors. Blood 109:610-612 (Pubitemid 46105959)
71. Santagostino E, Mannucci PM, Bianchi Bonomi A (2000)Guidelines on replacement therapy for haemophilia and inheritedcoagulation disorders in Italy. Haemophilia 6:1-10 (Pubitemid 30113894)
72. United Kingdom Haemophelia Centre Doctors' Organisation(2003) Guidelines on the selection and use of therapeutic productsto treat haemophilia and other hereditary bleeding disorders. Haemophilia 9:1-23
73. Hay CR, Baglin TP, Collins PW, Hill FG, Keeling DM (2000)The diagnosis and management of factor VIII and IX inhibitors: aguideline from the UK Haemophilia Centre Doctors' Organization(UKHCDO). Br J Haematol 111:78-90
74. Gringeri A, Mannucci PM (2005) Italian guidelines for thediagnosis and treatment of patients with haemophilia and inhibitors. Haemophilia 11:611-619 (Pubitemid 41631596)
75. Batlle J, Villar A, Liras A et al (2008) Consensus opinion for theselection and use of therapeutic products for the treatment ofhaemophilia in Spain. Blood Coagul Fibrinolysis 19:333-340